Improving estimation of liver fibrosis using combination and newer noninvasive biomarker scoring systems in hepatitis C-infected haemophilia patients

Haemophilia

Volumn 13, Issue 6, 2007, Pages 722-729

  Maor, Yaakov ^a   Cales P ^b   Bashari, D ^a   Kenet, G ^a   Lubetsky, A ^a   Luboshitz, J ^a   Schapiro, J M ^a   Penaranda G ^c   Bar Meir, S ^a   Martinowitz, U ^a   Halfon, P ^d  

^a SHEBA MEDICAL CENTER   (Israel)

^b UNIVERSITÉ D'ANGERS   (France)

^c CDL Pharma   (France)

^d Laboratoire Alphabio   (France)

Author keywords

FibroMeter; Fibrotest; Haemophilia; Hepatitis C; Liver biopsy; Noninvasive biomarkers of fibrosis

Indexed keywords

ASPARTATE AMINOTRANSFERASE; BIOLOGICAL MARKER; HYALURONIC ACID;

ADULT; ALGORITHM; ARTICLE; ASSAY; CLINICAL EVALUATION; CONTROLLED STUDY; DIAGNOSTIC ACCURACY; DIAGNOSTIC VALUE; FEMALE; HEMOPHILIA; HEPATITIS C; HUMAN; INTERMETHOD COMPARISON; LIVER BIOPSY; LIVER FIBROSIS; LIVER HISTOLOGY; MAJOR CLINICAL STUDY; MALE; NON INVASIVE PROCEDURE; PRIORITY JOURNAL; SCORING SYSTEM; THROMBOCYTE COUNT;

EID: 35548957275     PISSN: 13518216     EISSN: 13652516     Source Type: Journal    
DOI: 10.1111/j.1365-2516.2007.01548.x     Document Type: Article

References (33)

1. Yee TT, Griffioen A, Sabin CA, Dusheiko G, Lee CA. The natural history of HCV in a cohort of haemophilic patients infected between 1961 and 1985. Gut 2000; 47: 845-51.
2. Lee C, Dusheiko G. The natural history and antiviral treatment of hepatitis C in Haemophilia. Haemophilia 2002; 8: 322-9.
3. Maor Y, Bashari D, Kenet G et al. Hepatitis C at the israeli national hemophilia center. Haemophilia 2006; 12: 68-74.
4. Seeff LB, Hollinger FB, Alter HJ et al. Long-term mortality and morbidity of transfusion-associated non-A, non-B, and type C hepatitis: a National Heart, Lung, and Blood Institute collaborative study. Hepatology 2001; 33: 455-63.
5. Poynard T, Bedossa P, Opolon P. Natural history of liver fibrosis progression in patients with chronic hepatitis C. The OBSVIRC, METAVIR, CLINIVIR, and DOSVIRC groups. Lancet 1997; 349: 825-32.
6. Dienstag JL. The role of liver biopsy in chronic hepatitis C. Hepatology 2002; 36(Suppl.): S152-60.
7. Cadranel JF, Rufat P, Degos F. Practices of liver biopsy in France: results of a prospective nationwide survey. For the Group of Epidemiology of the French Association for the Study of the Liver (AFEF). Hepatology 2000; 32: 477-81.
8. Regev A, Berho M, Jeffers LJ et al. Sampling error and intraobserver variation in liver biopsy in patients with chronic HCV infection. Am J Gastroenterol 2002; 97: 2614-8.
9. Bedossa P, Dargere D, Paradis V. Sampling variability of liver fibrosis in chronic hepatitis C. Hepatology 2003; 38: 1449-57.
10. Theodore D, Fried MW, Kleiner DE et al. Liver biopsy in patients with inherited disorders of coagulation and chronic hepatitis C. Haemophilia 2004; 10: 413-21.
11. Shin JL, Teitel J, Swain MG et al. Virology and Immunology Committee of the Association of Hemophilia Clinic Directors of Canada. A Canadian multicenter retrospective study evaluating transjugular liver biopsy in patients with congenital bleeding disorders and hepatitis C: Is it safe and useful? Am J Hematol 2005; 78: 85-93.
12. Imbert-Bismut F, Ratziu V, Pieroni L, Charlotte F, Benhamou Y, Poynard T,
13. > for the MULTIVIRC group. Biochemical markers of liver fibrosis in patients with hepatitis C virus infection: A prospective study. Lancet 2001; 357: 1069-75.
14. Halfon P, Imbert-Bismut F, Messous D et al. A prospective assessment of the inter-laboratory variability of biochemical markers of fibrosis (Fibrotest) and activity (Actitest) in patients with chronic liver disease. Comp Hepatol 2002; 1: 3.
15. Poynard T, Munteanu M, Imbert-Bismut F et al. Prospective analysis of discordant results between biochemical markers and biopsy in patients with chronic hepatitis C. Clin Chem 2004; 50: 1344-55.
16. Le Calvez S, Thabut D, Messous D et al. The predictive value of fibrotest vs. APRI for the diagnosis of fibrosis in chronic hepatitis C. Hepatology 2004; 39: 862-3.
17. Halfon P, Bourlière M, Deydier R et al. Independent prospective multicenter validation of biochemical markers (fibrotest-actitest) for the prediction of liver fibrosis and activity in patients with chronic hepatitis C: The Fibropaca study. Am J Gastroenterol 2006; 101: 547-55.
18. Maor Y, Bashari D, Kenet G et al. Non-invasive biomarkers of liver Fibrosis in haemophilia patients with hepatitis C: Can you avoid Liver Biopsy? Haemophilia 2006; 12: 372-9.
19. Wai CT, Greenson JK, Fontana RJ et al. A simple non-invasive index can predict both significant fibrosis and cirrhosis in patients with chronic hepatitis C. Hepatology 2003; 38: 518-26.
20. Forns X, Ampurdanes S, Llovet JM et al. Identification of chronic hepatitis C patients without hepatic fibrosis by a simple predictive model. Hepatology 2002; 36: 986-92.
21. Bourlière M, Pénaranda G, Renou C et al. Validation and comparison of indexes or fibrosis and cirrhosis prediction in chronic hepatitis C patients: Proposal for a pragmatic approach classification without liver biopsies. J Viral Hepat 2006; 13: 659-70.
22. Calès P, Oberti F, Michalak S et al. A novel panel of blood markers to assess the degree of liver fibrosis. Hepatology 2005; 42: 1373-81.
23. Gerken G, Rothaar T, Rumi MG et al. Performance of the Cobas Amplicor HCV Monitor test, version 2.0, an automated reverse transcription-PCR quantitative system for hepatitis C virus load determination. J Clin Microbiol 2000; 38: 2210-4.
24. Halfon P, Trimoulet P, Bourlière M et al. Hepatitis C virus genotyping based on 5′ noncoding sequence analysis (Trugene). J Clin Microbiol 2001; 39: 1771-3.
25. Croquet V, Vuillemin E, Ternisien C et al. Prothrombin index is an indirect marker of severe liver fibrosis. Eur J Gastroenterol Hepatol 2002; 14: 1133-41.
26. Halfon P, Bourlière M, Pénaranda G et al. Accuracy of hyaluronic acid level for predicting liver fibrosis stages in patients with hepatitis C virus. Comp Hepatol 2005; 4: 6.
27. Poynard T. Diagnosis method of inflammatory or cancerous disease using the biochemical markers. US Patent 6,631,330 B1, 2003.
28. Poynard T, Zoulim F, Ratziu V et al. Longitudinal assessment of histology surrogate markers (FibroTest-ActiTest) during lamivudine therapy in patients with chronic hepatitis B infection. Am J Gastroenterol 2005; 100: 1970-80.
29. Castéra L, Vergniol J, Foucher J et al. Prospective comparison of transient elastography, Fibrotest, APRI and liver biopsy for the assessment of fibrosis in chronic hepatitis C. Gastroenterology 2005; 128: 343-50.
30. Sebastiani G, Vario A, Guido M et al. Stepwise combination algorithms of non-invasive markers to diagnose significant fibrosis in chronic hepatitis C. J Hepatol 2006; 44: 686-93.
31. Halfon P, Bacq Y, De Muret A et al. Comparison of test performance profile for blood tests of liver fibrosis in chronic hepatitis C. J Hepatol 2007; 46: 395-402.
32. Adams LA, Bulsara M, Rossi E et al. Hepascore: An accurate validated predictor of liver fibrosis in chronic hepatitis C infection. Clin Chem 2005; 51: 1867-73.
33. Pilette C, Rousselet M, Bedossa P et al. Histopathological evaluation of liver fibrosis: Quantitative image analysis vs. semi-quantitative scores: Comparison with serum markers. J Hepatol 1998; 28: 439-46.